Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | EYA2 | O00167 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentetic Acid SCHEMBL1812238 | 0.97 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL8372011 | 0.97 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL5056266 | 0.97 | KDM4E (0.68) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL2800920 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL1478010 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL5193980 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL6670902 | 0.94 | KDM4E (0.65) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL5352521 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL2274186 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL1477452 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11676750-B2 | Magnetic levitation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | claimed |
| CN-115590824-A | Polyvinyl alcohol embolism microsphere with developer and preparation method and application thereof | 浙江大学（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-108289970-B | Formulations comprising a combination of MRI contrast agents | 通用电气医疗集团股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-20220013268-A1 | MAGNETIC LEVITATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-01-13 | — | — | US | claimed |
| CN-113728232-A | IL-4R as a biomarker in cancer | 梅迪塞纳医疗股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-107899025-B | Glucan-gadolinium MRI nano developer and preparation method thereof | 上海交通大学 | 2020-12-11 | — | — | CN | claimed |
| CN-111405911-A | I L-4 fusion preparation for treating Central Nervous System (CNS) tumors | 梅迪塞纳医疗股份有限公司 | 2020-07-10 | — | — | CN | claimed |
| US-10702612-B2 | Conjugated polymer-based nanoprobe and preparation method and application thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2020-07-07 | — | — | US | claimed |
| US-20120065384-A1 | FLUORESCENT MRI PROBE | THE UNIVERSITY OF TOKYO (JP) | 2012-03-15 | — | — | US | claimed |
| JP-4790215-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| EP-1107985-A1 | BASIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | NST Neurosurvival Technologies Ltd. (IL) | 2001-06-20 | — | — | EP | claimed |
| WO-2001018031-A2 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2001-03-15 | — | — | WO | claimed |
| WO-2000011026-A1 | BASIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2000-03-02 | — | — | WO | claimed |
| EP-0467031-B1 | Medical-grade lipid-coated microbubbles, paramagnetic labelling thereof and their therapeutic use | CAVITATION CONTROL TECHNOLOGY (US) | 1997-07-30 | — | — | EP | claimed |
| US-5514379-A | Hydrogel compositions and methods of use | THE GENERAL HOSPITAL CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| WO-1995033494-A1 | EMULSIONS OF PARAMAGNETIC CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING (MRI), CONTAINING AN ORGANIC CHELATOR HAVING AN UNSATURATED ALIPHATIC GROUP | HEMAGEN/PFC (US) | 1995-12-14 | — | — | WO | claimed |
| US-5362475-A | Salt of gadolinium diethylenetriaminepentaacetic acid (gadofosveset salt) | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-11-08 | — | — | US | claimed |
| WO-1994003155-A1 | HYDROGEL COMPOSITIONS AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1994-02-17 | — | — | WO | claimed |
| EP-0467031-A2 | Medical-grade lipid-coated microbubbles, paramagnetic labelling thereof and their therapeutic use | CAVITATION-CONTROL TECHNOLOGY, INC. (US) | 1992-01-22 | — | — | EP | claimed |
| US-4957939-A | AMINOCARBOXYLIC ACIDS, MEDICAL IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702612-B2 | Conjugated polymer-based nanoprobe and preparation method and application thereof | CD69, MYD88, VEGFA | KDM4E 4770/4885ALOX15 2473/4885MAPT 530/4885 |
| US-20120065384-A1 | FLUORESCENT MRI PROBE | GLRA1, GLRA3, GDI1 | KDM4E 4398/4885ALOX15 4566/4885MAPT 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.